Sepsis - Pipeline Review, H1 2016

Published: Feb, 2016 | Pages: 263 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sepsis - Pipeline Review, H1 2016

Summary


Global Markets Direct's, 'Sepsis - Pipeline Review, H1 2016', provides an overview of the Sepsis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sepsis
- The report reviews pipeline therapeutics for Sepsis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Sepsis therapeutics and enlists all their major and minor projects
- The report assesses Sepsis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Sepsis

Reasons to buy


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Sepsis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Sepsis Overview 11
Therapeutics Development 12
Pipeline Products for Sepsis - Overview 12
Pipeline Products for Sepsis - Comparative Analysis 13
Sepsis - Therapeutics under Development by Companies 14
Sepsis - Therapeutics under Investigation by Universities/Institutes 20
Sepsis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Sepsis - Products under Development by Companies 24
Sepsis - Products under Investigation by Universities/Institutes 29
Sepsis - Companies Involved in Therapeutics Development 31
Adrenomed AG 31
Altor BioScience Corporation 32
Am-Pharma B.V. 33
Arch Biopartners, Inc. 34
Aridis Pharmaceuticals LLC 35
Asahi Kasei Pharma Corp. 36
Baxalta Incorporated 37
Biomedica Management Corporation 38
Boehringer Ingelheim GmbH 39
Bristol-Myers Squibb Company 40
Cell2B S.A. 41
Chiesi Farmaceutici SpA 42
Chiome Bioscience, Inc. 43
Cilian AG 44
Cognosci, Inc. 45
Diomune S.L 46
Endacea, Inc. 47
Evec, Inc. 48
Ferring International Center S.A. 49
Huons Co., Ltd. 50
Immune Response BioPharma, Inc. 51
Immunethep, SA 52
ImmunNovative Developments SL 53
InflaRx GmbH 54
Inotrem S.A. 55
Lead Discovery Center GmbH 56
Lixte Biotechnology Holdings, Inc. 57
Merck & Co., Inc. 58
Navigen Pharmaceuticals, Inc. 59
Noxxon Pharma AG 60
Ocata Therapeutics, Inc. 61
OncoImmune, Inc. 62
Opsona Therapeutics Limited 63
Orion Oyj 64
Peptinov SAS 65
Pharmazz, Inc. 66
ProThera Biologics, LLC. 67
Ra Pharmaceuticals, Inc. 68
Ribomic Inc. 69
Silence Therapeutics Plc 70
Spider Biotech 71
Stemedica Cell Technologies, Inc. 72
Syntiron LLC 73
TaiRx, Inc. 74
Takeda Pharmaceutical Company Limited 75
Therakind Limited 76
TiGenix NV 77
VBS Pharmaceuticals 78
XImmune AB 79
Sepsis - Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Target 81
Assessment by Mechanism of Action 84
Assessment by Route of Administration 87
Assessment by Molecule Type 89
Drug Profiles 91
3K3A-APC - Drug Profile 91
7-H9 - Drug Profile 93
AB-022 - Drug Profile 94
AcPepA - Drug Profile 95
adrecizumab - Drug Profile 96
ALT-836 - Drug Profile 97
AM-12 - Drug Profile 99
AM/AMBP-1 - Drug Profile 100
Aspidasept - Drug Profile 103
Atu-111 - Drug Profile 104
bacterial sepsis vaccine - Drug Profile 105
BaxB-01 - Drug Profile 106
BaxG-03 - Drug Profile 107
BaxM-159 - Drug Profile 108
BC-1215 - Drug Profile 109
BI-113823 - Drug Profile 110
BMS-936559 - Drug Profile 111
BRL-44408 - Drug Profile 112
BTZO-2 - Drug Profile 114
C-10 - Drug Profile 115
CAR Peptide - Drug Profile 117
ceftaroline fosamil - Drug Profile 118
COG-133 - Drug Profile 121
Cx-611 - Drug Profile 123
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 125
Drugs to Inhibit Sialidase for Sepsis - Drug Profile 126
Escherichia coli vaccine - Drug Profile 127
EV-007156 - Drug Profile 128
Glyco-23 - Drug Profile 129
HBN-1 - Drug Profile 130
HBN-3 - Drug Profile 131
HBN-4 - Drug Profile 132
HU-003 - Drug Profile 133
IFX-1 - Drug Profile 134
ImmStem - Drug Profile 135
ImmuneSafe - Drug Profile 136
IND-006 - Drug Profile 138
IR-999 - Drug Profile 139
Klebsiella pneumoniae vaccine - Drug Profile 140
L-257 - Drug Profile 141
L-97-1 - Drug Profile 142
LB-100 - Drug Profile 144
LB-1148 - Drug Profile 146
levosimendan - Drug Profile 147
Motrem - Drug Profile 149
M-33 - Drug Profile 151
M-6229 - Drug Profile 152
meropenem - Drug Profile 153
Metablok - Drug Profile 154
Micselon - Drug Profile 155
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 156
Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 157
Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 158
Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 159
Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 160
Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 162
NAV-838 - Drug Profile 164
NOXD-20 - Drug Profile 166
OPN-305 - Drug Profile 167
Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 169
PMZ-2010 - Drug Profile 171
Polysaccharide for Sepsis - Drug Profile 173
Protein for Inflammation and Bacterial Sepsis - Drug Profile 174
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 175
Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 176
R-190 - Drug Profile 177
RA-101295 - Drug Profile 179
RBM-005 - Drug Profile 180
Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis - Drug Profile 181
Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 182
Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 184
Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 185
Recombinant Protein for Sepsis - Drug Profile 186
Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 187
Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 189
SAN-101 - Drug Profile 190
SB-056 - Drug Profile 191
selepressin - Drug Profile 192
Slit2N - Drug Profile 193
Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 195
Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile 196
Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 197
Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 198
Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 199
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 201
SP-14 - Drug Profile 202
SP-9 - Drug Profile 203
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 204
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 205
Synthetic Peptide to Inhibit TREM-1 for Cancer, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 207
Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 208
Synthetic Peptides for Infectious Disease - Drug Profile 209
Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 210
Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 211
Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile 212
TF-0003 - Drug Profile 213
thrombomodulin alfa - Drug Profile 214
tosatoxumab - Drug Profile 216
TRX-306 - Drug Profile 218
vancomycin hydrochloride - Drug Profile 219
Yersinia pestis vaccine - Drug Profile 220
Sepsis - Recent Pipeline Updates 221
Sepsis - Dormant Projects 240
Sepsis - Discontinued Products 246
Sepsis - Product Development Milestones 248
Featured News & Press Releases 248
Appendix 255
Methodology 255
Coverage 255
Secondary Research 255
Primary Research 255
Expert Panel Validation 255
Contact Us 255
Disclaimer 256

List of Tables

Number of Products under Development for Sepsis, H1 2016 19
Number of Products under Development for Sepsis - Comparative Analysis, H1 2016 20
Number of Products under Development by Companies, H1 2016 22
Number of Products under Development by Companies, H1 2016 (Contd..1) 23
Number of Products under Development by Companies, H1 2016 (Contd..2) 24
Number of Products under Development by Companies, H1 2016 (Contd..3) 25
Number of Products under Development by Companies, H1 2016 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2016 27
Comparative Analysis by Late Stage Development, H1 2016 28
Comparative Analysis by Clinical Stage Development, H1 2016 29
Comparative Analysis by Early Stage Development, H1 2016 30
Products under Development by Companies, H1 2016 31
Products under Development by Companies, H1 2016 (Contd..1) 32
Products under Development by Companies, H1 2016 (Contd..2) 33
Products under Development by Companies, H1 2016 (Contd..3) 34
Products under Development by Companies, H1 2016 (Contd..4) 35
Products under Investigation by Universities/Institutes, H1 2016 36
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 37
Sepsis - Pipeline by Adrenomed AG, H1 2016 38
Sepsis - Pipeline by Altor BioScience Corporation, H1 2016 39
Sepsis - Pipeline by Am-Pharma B.V., H1 2016 40
Sepsis - Pipeline by Arch Biopartners, Inc., H1 2016 41
Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 42
Sepsis - Pipeline by Asahi Kasei Pharma Corp., H1 2016 43
Sepsis - Pipeline by Baxalta Incorporated, H1 2016 44
Sepsis - Pipeline by Biomedica Management Corporation, H1 2016 45
Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 46
Sepsis - Pipeline by Bristol-Myers Squibb Company, H1 2016 47
Sepsis - Pipeline by Cell2B S.A. , H1 2016 48
Sepsis - Pipeline by Chiesi Farmaceutici SpA, H1 2016 49
Sepsis - Pipeline by Chiome Bioscience, Inc., H1 2016 50
Sepsis - Pipeline by Cilian AG, H1 2016 51
Sepsis - Pipeline by Cognosci, Inc., H1 2016 52
Sepsis - Pipeline by Diomune S.L, H1 2016 53
Sepsis - Pipeline by Endacea, Inc., H1 2016 54
Sepsis - Pipeline by Evec, Inc., H1 2016 55
Sepsis - Pipeline by Ferring International Center S.A., H1 2016 56
Sepsis - Pipeline by Huons Co., Ltd., H1 2016 57
Sepsis - Pipeline by Immune Response BioPharma, Inc., H1 2016 58
Sepsis - Pipeline by Immunethep, SA, H1 2016 59
Sepsis - Pipeline by ImmunNovative Developments SL, H1 2016 60
Sepsis - Pipeline by InflaRx GmbH, H1 2016 61
Sepsis - Pipeline by Inotrem S.A., H1 2016 62
Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2016 63
Sepsis - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 64
Sepsis - Pipeline by Merck & Co., Inc., H1 2016 65
Sepsis - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016 66
Sepsis - Pipeline by Noxxon Pharma AG, H1 2016 67
Sepsis - Pipeline by Ocata Therapeutics, Inc., H1 2016 68
Sepsis - Pipeline by OncoImmune, Inc., H1 2016 69
Sepsis - Pipeline by Opsona Therapeutics Limited, H1 2016 70
Sepsis - Pipeline by Orion Oyj, H1 2016 71
Sepsis - Pipeline by Peptinov SAS, H1 2016 72
Sepsis - Pipeline by Pharmazz, Inc., H1 2016 73
Sepsis - Pipeline by ProThera Biologics, LLC., H1 2016 74
Sepsis - Pipeline by Ra Pharmaceuticals, Inc., H1 2016 75
Sepsis - Pipeline by Ribomic Inc., H1 2016 76
Sepsis - Pipeline by Silence Therapeutics Plc, H1 2016 77
Sepsis - Pipeline by Spider Biotech, H1 2016 78
Sepsis - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 79
Sepsis - Pipeline by Syntiron LLC, H1 2016 80
Sepsis - Pipeline by TaiRx, Inc., H1 2016 81
Sepsis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 82
Sepsis - Pipeline by Therakind Limited, H1 2016 83
Sepsis - Pipeline by TiGenix NV, H1 2016 84
Sepsis - Pipeline by VBS Pharmaceuticals, H1 2016 85
Sepsis - Pipeline by XImmune AB, H1 2016 86
Assessment by Monotherapy Products, H1 2016 87
Number of Products by Stage and Target, H1 2016 89
Number of Products by Stage and Mechanism of Action, H1 2016 92
Number of Products by Stage and Route of Administration, H1 2016 95
Number of Products by Stage and Molecule Type, H1 2016 97
Sepsis Therapeutics - Recent Pipeline Updates, H1 2016 228
Sepsis - Dormant Projects, H1 2016 247
Sepsis - Dormant Projects (Contd..1), H1 2016 248
Sepsis - Dormant Projects (Contd..2), H1 2016 249
Sepsis - Dormant Projects (Contd..3), H1 2016 250
Sepsis - Dormant Projects (Contd..4), H1 2016 251
Sepsis - Dormant Projects (Contd..5), H1 2016 252
Sepsis - Discontinued Products, H1 2016 253
Sepsis - Discontinued Products (Contd..1), H1 2016 254